Drugs / AZD2423
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01233830 | Nov 2010 → Mar 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00977626 | Oct 2009 → May 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00970775 | Aug → Dec 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00940212 | Jul → Nov 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01215279 | Oct 2010 → Mar 2011 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01200524 | Oct 2010 → Apr 2012 | neuralgia | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01153321 | Oct 2010 → Jul 2011 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01201317 | Sep 2010 → Jun 2011 | neuropathy, painful | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01215279 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 2 antagonist” CHEMBL3545221 ↗ |
| Route | Oral | “oral, single administration” NCT00940212 ↗ |
| Target | CCR2 | “C-C chemokine receptor type 2 antagonist” CHEMBL3545221 ↗ |